| First Author | Gotoh K | Year | 2012 |
| Journal | J Neurochem | Volume | 120 |
| Issue | 5 | Pages | 752-64 |
| PubMed ID | 22146087 | Mgi Jnum | J:182778 |
| Mgi Id | MGI:5316568 | Doi | 10.1111/j.1471-4159.2011.07617.x |
| Citation | Gotoh K, et al. (2012) A novel anti-inflammatory role for spleen-derived interleukin-10 in obesity-induced hypothalamic inflammation. J Neurochem 120(5):752-64 |
| abstractText | Obesity can be associated with systemic low-grade inflammation that contributes to obesity-related metabolic disorders. Recent studies raise the possibility that hypothalamic inflammation contributes to the pathogenesis of diet-induced obesity (DIO), while another study reported that obesity decreases the expression of pro-inflammatory cytokines in spleen. The following study examines the hypothesis that obesity suppresses the splenic synthesis of the anti-inflammatory cytokine, interleukin (IL)-10, thereby resulting in chronic hypothalamic inflammation. The results showed that due to oxidative stress or apoptosis, the synthesis of splenic IL-10 was decreased in DIO when compared with non-obesity rats. Splenectomy (SPX) accelerated DIO-induced inflammatory responses in the hypothalamus. Interestingly, SPX suppressed the DIO-induced increases in food intake and body weight and led to a hypothalamic pro-inflammatory state that was similar to that produced by DIO, indicating that hypothalamic inflammation exerts a dual effect on energy metabolism. These SPX-induced changes were inhibited by the systemic administration of IL-10. Moreover, SPX had no effect on hypothalamic inflammatory responses in IL-10-deficient mice. These data suggest that spleen-derived IL-10 plays an important role in the prevention of hypothalamic inflammation and may be a therapeutic target for the treatment of obesity and hypothalamic inflammation. |
